General information, not medical advice This article summarizes public regulatory news. It does not replace a doctor's advice. Wegovy and Mounjaro are prescription-only medicines — their use falls exclusively within the medical framework described below.

What's actually changing

Since June 15, 2026, French Health Insurance (Assurance Maladie) covers 65% of the price of Wegovy and Mounjaro for the weight-control indication — a rate that reaches 100% for patients with a long-term condition (ALD, affection de longue durée), which applies to the majority of people who are actually eligible. Mounjaro also benefits from reimbursement for type 2 diabetes.

Who is eligible?

Reimbursement is not available to anyone wanting to lose a few pounds. It targets severe forms of obesity, as a second-line option, after a well-managed nutritional program has failed:

The reimbursed initial prescription is limited to a specialized pathway (specialized obesity centers, university hospitals, affiliated endocrinologists) — a general practitioner can handle renewal, but not initiation of treatment under the reimbursed scheme.

Understanding the mechanisms: single, dual, and triple GLP-1 agonists

Wegovy, Ozempic and Mounjaro belong to the family of GLP-1 analogs, molecules that mimic a natural satiety hormone. They differ based on the number of receptors they activate simultaneously:

Single agonist
Semaglutide
The molecule behind Ozempic and Wegovy. Activates a single receptor: GLP-1.
Dual agonist
Tirzepatide
The molecule behind Mounjaro. Activates two receptors: GLP-1 and GIP.
Triple agonist
Retatrutide
Activates three receptors: GLP-1, GIP and glucagon. A research peptide, not approved as a medicine.
An important distinction Semaglutide and tirzepatide are approved medicines, available by medical prescription, with phase 3 clinical trials and market authorization. Retatrutide is, as of now, a research peptide — it has no market authorization and is not intended for human use. The number of receptors activated is a mechanistic fact, not a ranking of efficacy or safety: these are two different product categories, regulated differently, that cannot be compared on the same footing.

Retatrutide is the subject of ongoing clinical trials and attracts strong interest in the scientific literature as a research candidate for combined metabolic pathways. To learn more about what the current literature documents, see our article human studies: retatrutide, tirzepatide, BPC-157, GHK-Cu. Retatrutide as a research peptide is available on our dedicated product page, reserved for laboratory use.

Sources

The research peptides discussed on this site are sold exclusively for scientific research purposes (Research Use Only), not intended for human or animal consumption.